2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179803
    C20 Ceramide (d17:1/20:0) 474944-00-8 98%
    C20 Ceramide (d17:1/20:0) is a ceramide.
    C20 Ceramide (d17:1/20:0)
  • HY-179806
    C24:1 Ceramide (d17:1/24:1(15Z)) 352518-77-5 98%
    C24:1 Ceramide (d17:1/24:1(15Z)) is a ceramide.
    C24:1 Ceramide (d17:1/24:1(15Z))
  • HY-179809
    C24 Ceramide (d17:1/24:0) 123065-50-9 98%
    C24 Ceramide (d17:1/24:0) is a ceramide.
    C24 Ceramide (d17:1/24:0)
  • HY-179826
    C18 Ceramide (d17:1/18:0) 123065-42-9 98%
    C18 Ceramide (d17:1/18:0) is a ceramide.
    C18 Ceramide (d17:1/18:0)
  • HY-180122
    (Rac)-Azide-deoxy-ascomycin-O-ethylene 146877-36-3
    (Rac)-Azide-deoxy-ascomycin-O-ethylene, a nitrogen-containing compound, is a derivative of a macrolide-type immunosuppressant.
    (Rac)-Azide-deoxy-ascomycin-O-ethylene
  • HY-180182
    RXR agonist 3
    RXR agonist 3 (Compound 35) is a potent, partial RXR agonist (EC50s: 3, 3, 8 nM for RXRα, RXRβ, RXRγ, respectively). RXR agonist 3 can be used in the research of Alzheimer's disease, multiple sclerosis, and lymphoma.
    RXR agonist 3
  • HY-180210
    Ghrelin receptor full agonist-3 2243167-93-1
    Ghrelin receptor full agonist-3 (Compound 22) is a selective, potent and orally active ghrelin receptor full agonist with an EC50 of 1.8 nM. Ghrelin receptor full agonist-3 can stimulate pulsatile secretion of growth hormone (GH), significantly increasing the frequency and duration of GH secretion, thereby inducing a sustained increase in insulin-like growth factor-1 (IGF-1) levels. Ghrelin receptor full agonist-3 can be used for the researches of cancer and chronic obstructive pulmonary disease.
    Ghrelin receptor full agonist-3
  • HY-18054A
    BVT-2733 hydrochloride 376641-65-5 98%
    BVT-2733 hydrochloride is a potent, selective and orally active nonsteroidal 11β-HSD1 inhibitor. BVT-2733 hydrochloride is more potent against mouse 11β-HSD1 enzyme (IC50=96 nM) than against human 11β-HSD1 enzyme (IC50=3341 nM). BVT-2733 hydrochloride has the potential to be used in the study of arthritis and obesity-related diseases.
    BVT-2733 hydrochloride
  • HY-18054R
    BVT 2733 (Standard) 376640-41-4 98%
    BVT 2733 (Standard) is the analytical standard of BVT 2733. This product is intended for research and analytical applications. BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease.
    BVT 2733 (Standard)
  • HY-180560
    PHD-IN-5 2924181-95-1
    PHD-IN-5 (ISM4808) is an orally active PHD inhibitor that can be used for studying anemia in chronic kidney disease.
    PHD-IN-5
  • HY-180908
    IRAK4-IN-34 2411498-83-2
    IRAK4-IN-34 (compound 19) is a potent, selective, and orally active Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 0.73 nM. IRAK4-IN-34 exhibits good selectivity vs both hERG and other kinases. IRAK4-IN-34 shows favorable in vivo PK properties. IRAK4-IN-34 can be used for inflammatory diseases research.
    IRAK4-IN-34
  • HY-181085
    RD0448 98%
    RD0448 is a potent inhibitor of DYRK1A, DYRK1B, and DYRK2. RD0448 selectively targets the non-native (folded intermediate) state of DYRK1A and DYRK1B. The binding site of RD0448 is hidden in the native state of DYRK1A and DYRK1B, and as a stabilizing binder, it binds tightly to both DYRK1A and DYRK1B, forming a stable complex with slow dissociation kinetics. In contrast, RD0448 targets the native state of DYRK2 without selectivity between its native and non-native states, acting as a weak binder with weaker binding affinity to DYRK2 and forming a rapidly dissociating complex.
    RD0448
  • HY-181095
    Xanthine oxidase-IN-22 3075445-37-0 98%
    Xanthine oxidase-IN-22 is an orally active inhibitor of xanthine oxidase (XO) (IC50: 0.0034 μM). Xanthine oxidase-IN-22 exhibits a mixed-type inhibition mode against XO. Xanthine oxidase-IN-22 reduces serum uric acid levels in mice. Xanthine oxidase-IN-22 can be used in research related to hyperuricemia and gout.
    Xanthine oxidase-IN-22
  • HY-181102
    TGR5 agonist 10 3081614-92-5
    TGR5 agonist 10 is a selective, allosteric and orally active Takeda G protein coupled receptor 5 (TGR5) agonist with EC50s of 0.8 μM and 0.6 μM for human TGR5 and mouse TGR5, respectively. TGR5 agonist 10 demonstrates selectivity for TGR5 over FXR. TGR5 agonist 10 activates hTGR5 and mTGR5 to induce cAMP accumulation, and positively modulates lithocholic acid functional activity and potency at hTGR5, with higher selectivity for cAMP formation over β-arrestin2 recruitment. TGR5 agonist 10 exerts glucose-lowering effects in Mus musculus oral glucose tolerance tests. TGR5 agonist 10 can be used for the research of diabetes.
    TGR5 agonist 10
  • HY-181176
    DEMAMP 98%
    DEMAMP is an antioxidant. DEMAMP exhibits scavenging effects on DPPH and H2O2 free radicals, with IC50 values of 0.60 and 0.48 mg/mL, respectively. Molecular docking simulations show that DEMAMP potently inhibits NADPH oxidase and the Mpro and RdRp proteins of SARS-CoV-2, and ADMET analysis confirms that it has favorable oral bioavailability. DEMAMP can be used in studies related to COVID-19.
    DEMAMP
  • HY-181485
    GPR68 antagonist 1
    GPR68 antagonist 1 is a GPR68 antagonist with an IC50 of 81 nM. GPR68 antagonist 1 inhibits the mouse GPR68-mediated cAMP signaling pathway with an IC50 of 179 nM. GPR68 antagonist 1 alleviates disease symptoms in a dextran sulfate sodium (DSS) (HY-116282C)-induced mouse model of inflammatory bowel disease. GPR68 antagonist 1 is applicable to research related to inflammatory bowel disease.
    GPR68 antagonist 1
  • HY-181492
    Antifungal agent 155 hydrochloride 98%
    Antifungal agent 155 hydrochloride is an antifungal agent. Antifungal agent 155 hydrochloride induces bent, twisted, abnormally swollen hyphae, compromises fungal hyphal plasma membrane integrity, and triggers fungal cell death. Antifungal agent 155 hydrochloride can be used for the research of fusarium keratitis.
    Antifungal agent 155 hydrochloride
  • HY-181519
    ALR2/α-GLY-IN-1 98%
    ALR2/α-GLY-IN-1 is a potent dual-target inhibitor that targets aldose reductase ALR2 and α-glucosidase (IC50 values are 0.72 μM and 0.82 μM, respectively; Ki values are 1.67 μM and 1.37 μM, respectively). ALR2/α-GLY-IN-1 also acts as a DNA binder, which stably interacts with calf thymus double-stranded DNA through non-covalent interactions such as groove-binding mode and water-bridged hydrogen bonds. ALR2/α-GLY-IN-1 can be used in studies related to diabetes and its complications.
    ALR2/α-GLY-IN-1
  • HY-181588
    NR4A agonist-2 98%
    NR4A agonist-2 is a selective pan-NR4A agonist designed based on Vidofludimus (HY-14908), with a Kd of 0.10 μM against NR4A1, and EC50 values of 0.098 μM, 0.092 μM and 0.09 μM against Nur77, Nurr1, NOR-1, respectively. NR4A agonist-2 exhibits 47-fold selectivity over DHODH, and shows no cytotoxic activity at concentrations up to 10 μM. By binding to a specific surface pocket in the ligand-binding domain of Nurr1, NR4A agonist-2 inhibits the formation of Nurr1 homodimers, activates response elements such as NBRE, NurRE, DR5, and then potently induces the expression of neuroprotective genes including BDNF, SOD2, thereby exerting neuroprotective activity. NR4A agonist-2 can be used in the research of neurodegenerative diseases such as Parkinson's disease, dementia and multiple sclerosis.
    NR4A agonist-2
  • HY-181604
    MDH2-IN-2 3047410-41-0 98%
    MDH2-IN-2 is an orally active MDH2 inhibitor with an IC50 of 5.9 μM. MDH2-IN-2 reduces the levels of senescence markers and senescence-associated secretory phenotype (SASP) factors in mammalian cell models. MDH2-IN-2 extends the lifespan and improves the healthspan of Caenorhabditis elegans. MDH2-IN-2 alleviates tissue senescence in aged mice, inhibits SASP factors, and restores liver and kidney functions. MDH2-IN-2 is applicable for senescence-related research.
    MDH2-IN-2
Cat. No. Product Name / Synonyms Application Reactivity